Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06397963 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 2 to 3
    • Eligibility criteria expanded, about 1,156 words
    • Collaborators expanded, about 14 words
    v5
  2. Primary endpoint revisedv4
  3. Primary endpoint revised
    • Study sites: 1 to 2
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307 injection ) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
Trial Details
NCT Number NCT06397963
Lead Sponsor Grit Biotechnology
Collaborators: The Affiliated Hospital of Xuzhou Medical University, Beijing GoBroad Hospital, Beijing Arion Cancer Center
Conditions
(from sponsor)		 Solid Tumor, Adult
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov